Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002948 · ClinicalTrials.gov registry record · Phase 1
High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00002948: Clinical Trial Phase 1 study, sponsored by Yale University.
NCT00002948 is a Phase 1 study that was terminated before completion, run by Yale University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002948, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of high-dose topotecan and peripheral stem cell transplantation in treating patients with refractory cancer.
Interventions
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- DRUG topotecan hydrochloride
- PROCEDURE bone marrow ablation with stem cell support
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-10 |
| Est. Completion | 2004-01 |
| Phase | Phase 1 |
Why NCT00002948 stopped before completion
NCT00002948 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which peripheral blood stem cell transplantation is the first listed.
NCT00002948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002948 about?
NCT00002948 is a clinical study titled "High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of drugs and kill more tumor cells. PURPOSE: Phase I trial to study the ...
What is the current status of trial NCT00002948?
This trial is currently terminated. It is a Phase 1 study. The study started on 1996-10. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00002948?
The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG), bone marrow ablation with stem cell support (PROCEDURE).
Who is sponsoring clinical trial NCT00002948?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia